Stock Scorecard

Stock Summary for Lineage Cell Therapeutics Inc (LCTX) - $0.64 as of 11/20/2024 8:22:21 PM EST

Total Score

10 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LCTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LCTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LCTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LCTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LCTX (23 out of 90)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 2
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0

Financial Details for LCTX

Company Overview
Ticker LCTX
Company Name Lineage Cell Therapeutics Inc
Country USA
Description Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 0.64
Price 4 Years Ago 1.76
Last Day Price Updated 11/20/2024 8:22:21 PM EST
Last Day Volume 9,878,295
Average Daily Volume 479,824
52-Week High 1.61
52-Week Low 0.77
Last Price to 52 Week Low 16.88%

Valuation Measures
Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -9.65
Free Cash Flow Ratio 3.76
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 2.48
Total Cash Per Share 0.17
Book Value Per Share Most Recent Quarter 0.36
Price to Book Ratio 2.39
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 26.39
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 2

Share Statistics
Total Shares Outstanding 188,837,000
Market Capitalization 120,855,680
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.71%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 18.22%
Reported EPS 12 Trailing Months -0.13
Reported EPS Past Year -0.09
Reported EPS Prior Year -0.13
Net Income Twelve Trailing Months -20,111,000
Net Income Past Year -21,486,000
Net Income Prior Year -26,273,000
Quarterly Revenue Growth YOY -56.30%
5-Year Revenue Growth 12.39%
Operating Margin Twelve Trailing Months -4.17

Balance Sheet
Total Cash Most Recent Quarter 32,711,000
Total Cash Past Year 35,492,000
Total Cash Prior Year 57,875,000
Net Cash Position Most Recent Quarter 32,711,000
Net Cash Position Past Year 34,969,000
Long Term Debt Past Year 523,000
Long Term Debt Prior Year 523,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 63,419,000
Total Stockholder Equity Prior Year 73,339,000
Total Stockholder Equity Most Recent Quarter 66,186,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -23,056,000
Free Cash Flow Per Share Twelve Trailing Months -0.12
Free Cash Flow Past Year -29,240,000
Free Cash Flow Prior Year 646,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.01
MACD Signal 0.00
20-Day Bollinger Lower Band 0.80
20-Day Bollinger Middle Band 0.91
20-Day Bollinger Upper Band 1.02
Beta 1.28
RSI 57.05
50-Day SMA 1.03
150-Day SMA 1.27
200-Day SMA 1.57

System
Modified 11/19/2024 5:16:03 AM EST